Haemonetics Corporation (HAE) Stock Price
HAEStock
$118.28+137.65%52W
Market Cap$5.38B
P/E55.30x
PEG Ratio1.92
Div yield—
Beta0.61
HAE Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)85.66%
Price vs S&P 500 (4W)10.11%
PEG Ratio1.92
VGM Score58.17
P/E Ratio (Annual)55.30x
HAE Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $1.08 | $1.14 | +5.85%(+$0.06) | |
| Q1 2026 | $1.27 | $1.29 | +1.38%(+$0.02) | |
| Q4 2025 | $1.25 | $1.31 | +4.77%(+$0.06) | |
| Q3 2025 | $1.11 | $1.27 | +14.35%(+$0.16) | |
| Q2 2025 | $1.02 | $1.10 | +8.31%(+$0.08) |
HAE Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.07
4.07
4.07
4.07
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
HAEHaemonetics Corporation | C | C | A | 4.0x | 8.9% | 59.1% | 11.9% | $118.28 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
About Haemonetics Corporation
Haemonetics provides medical solutions for blood and plasma collection, processing, and transfusion services across three business segments: plasma, blood center, and hospital. The plasma and hospital segments drive growth due to robust market potential, while the blood center segment faces competitive headwinds. Revenue is generated through sales of disposable collection and processing sets and supporting equipment.